Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects

Next Previous
Trial Profile

An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 2647544 (Primary) ; GSK 2647544 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 29 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
  • 20 Dec 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
  • 21 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top